Etoricoxib 60 mg – [15 tablets]

Description

Etoricoxib tablets is a type of NSAID (non-steroidal anti-inflammatory drug) used to treat a variety of conditions, from mild to moderate pain to inflammation. The tablets are available in a variety of strengths and are used to treat pain and inflammation associated with osteoarthritis, rheumatoid arthritis, gout, and ankylosing spondylitis.

Etoricoxib Pharmacodynamics
When administered orally at therapeutic concentrations, etoricoxib is a selective inhibitor of cyclooxygenase-2 (COX-2). In clinical pharmacological studies, etoricoxib inhibited COX-2 in a dose-dependent manner with no effect on COX-1 at a daily dose up to 150 mg. Etoricoxib does not inhibit the synthesis of prostaglandins in the gastric mucosa and does not affect platelet function.
Cyclooxygenase is responsible for the formation of prostaglandins. Two isoforms of cyclooxygenase, COX-1 and COX-2, have been isolated. COX-2 is an isoenzyme that is induced by various proinflammatory mediators and is considered the main enzyme responsible for the synthesis of prostanoid mediators of pain, inflammation and fever. COX-2 is involved in the processes of ovulation, implantation and closure of the arterial duct, regulation of kidney function and the central nervous system (induction of fever, sensation of pain, cognitive function), and may also play a role in the process of ulcer healing. COX-2 has been detected in the tissues surrounding gastric ulcers in humans, but its importance in ulcer healing has not been established.

Efficacy
In patients with osteoarthritis (OA), Etoricoxib Lekas tablets, when administered at a dose of 60 mg once daily, provided a significant reduction in pain and improvement in patients’ assessment of their condition. These favorable effects were observed on the second day of treatment and persisted for 52 weeks. Studies of etoricoxib at a dose of 30 mg once a day demonstrated a higher efficacy compared to placebo during the treatment period of 12 weeks (using similar methods of assessment). In a study conducted to determine the optimal dose, etoricoxib, when used at a dose of 60 mg, demonstrated significantly greater improvement than the 30 mg dose for all 3 primary endpoints after 6 weeks of treatment. The 30 mg dose has not been studied in hand joint OA.

In patients with rheumatoid arthritis (RA), Etoricoxib Lekas tablets, when administered at 60 mg and 90 mg once daily, provided both a significant reduction in pain and inflammation and improved mobility. In studies evaluating the 60 mg and 90 mg doses of etoricoxib, these favorable effects persisted for a treatment period of 12 weeks.

In patients with attacks of acute gouty arthritis, Etoricoxib Lekas tablets, when administered at a dose of 120 mg once daily for a treatment period of 8 days reduced moderate to severe joint pain and inflammation. The efficacy was comparable to that of indomethacin when used in a dose of 50 mg 3 times a day. Pain reduction was noted as early as 4 h after the start of treatment.

In patients with ankylosing spondylitis, Etoricoxib Lekas tablets at a dose of 90 mg once a day provided a significant reduction in back pain, inflammation, stiffness, as well as improved function. Clinical efficacy of etoricoxib was observed as early as the second day of treatment and was maintained throughout the entire treatment period of 52 weeks. In a second study comparing an etoricoxib 60 mg dose and a 90 mg dose, etoricoxib at 60 mg once daily and 90 mg once daily demonstrated similar efficacy compared to naproxen 1000 mg once daily.

In a clinical study of pain after dental surgery, Etoricoxib Lekas tablets in a dose of 90 mg once daily for 3 days was administered. In a subgroup of patients with moderate pain at baseline, etoricoxib had the same analgesic effect as ibuprofen at a dose of 600 mg (16.11 vs. 16.39 P=0.722), and was superior to the paracetamol/codeine combination at a dose of 600 mg/60 mg (11.00; P<0.001) and placebo (6.84; P<0.001) according to the overall first 6 h pain reduction score (TOPAR6). The proportion of patients who required rapid-acting pain medication within the first 24 h after taking the study drugs was 40.8% with etoricoxib at 90 mg, 25.5% with ibuprofen at 600 mg every 6 h, and 46.7% with the paracetamol/codein combination at 600 mg/60 mg every 6 h, compared with 76.2% in the placebo group. In this study, the median onset of action (perceived pain reduction) with etoricoxib at a dose of 90 mg was 28 min after drug administration.

• Treatment of chronic low back pain.
• Symptomatic therapy of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, pain and inflammation associated with acute gouty arthritis.
• Short-term therapy for moderate acute pain after dental surgery.
• The decision to prescribe a COX-2 selective inhibitor must be justified taking into account the overall risks for each individual patient (see sections “Contraindications” and “Special Indications”).

• Hypersensitivity to any component of the drug;
• Gastric and 12 duodenal ulcer in the acute stage or active gastrointestinal bleeding;
• complete or incomplete combination of bronchial asthma, acute rhinitis, recurrent nasal and paranasal sinus polyposis and intolerance to acetylsalicylic acid or intolerance to other NSAIDs (including anamnesis);
• pregnancy and breastfeeding;
• severe hepatic impairment (serum albumin <25 g/l or ?10 on the Child-Pugh scale);
• severe renal insufficiency (creatinine clearance (CK) <30 ml/min);
• Children under 16 years of age;
• inflammatory bowel disease;
• chronic heart failure (NYHA functional class II-IV);
• uncontrolled arterial hypertension with persistently elevated BP above 140/90 mmHg;
• confirmed coronary heart disease, peripheral arterial disease and/or cerebrovascular disease;
• lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
• confirmed hyperkalemia;
• progressive renal disease.